Item 5.02(b). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 25, 2022, Eric Cheng notified Medicus Sciences Acquisition Corp. (the "Company") that he was resigning as Chief Business Officer of the Company effective immediately. Mr. Cheng's resignation was not the result of any disagreement with the Company. On March 25, 2022, the Board of Directors of the Company appointed Neil Puri as Chief Business Officer of the Company, effective immediately.

Dr. Puri joined Altium Capital Management LP in August 2021 as an Analyst focused on investments within the healthcare sector. Dr. Puri was previously a Senior Analyst at Alera Partners, a healthcare-dedicated investment fund from April 2021 to August 2021. He began his Wall Street career as a Sr. Associate in Biotechnology Equity Research at BMO Capital Markets from 2018 to 2019, and has had other sell-side positions focused on biotechnology including Equity Research at SVB Leerink from 2019 to 2022 and Investment Banking at Jefferies from 2020 to 2021. Before entering finance, Dr. Puri obtained his board certification in Internal Medicine, and has practiced clinical medicine following completion of his Internal Medicine Residency at Thomas Jefferson University Hospital in 2012. Dr. Puri earned his B.S. in Economics from Duke University, then attended Rutgers - Robert Wood Johnson Medical School where he earned his M.D. In addition, he earned his M.B.A. from the University of Chicago - Booth School of Business.

There are no arrangements or understandings between Dr. Puri and any other person pursuant to which any of Dr. Puri was selected as an officer of the Company. There are no family relationships between Dr. Puri and any of the Company' s other directors or executive officers.

There are no transactions between the Company and Dr. Puri that are subject to disclosure under Item 404(a) of Regulation S-K.

© Edgar Online, source Glimpses